Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Other financing activities (2018 - 2022)

OptimizeRx (OPRX) has disclosed Other financing activities for 9 consecutive years, with $4.3 million as the latest value for Q3 2022.

  • Quarterly Other financing activities rose 324.33% to $4.3 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $12.5 million through Sep 2022, up 317.05% year-over-year, with the annual reading at $1.9 million for FY2018, N/A changed from the prior year.
  • Other financing activities hit $4.3 million in Q3 2022 for OptimizeRx, up from $4.0 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $4.3 million in Q3 2022 to a low of $408087.0 in Q2 2019.
  • Historically, Other financing activities has averaged $1.4 million across 5 years, with a median of $754512.0 in 2020.
  • Biggest five-year swings in Other financing activities: decreased 22.84% in 2021 and later skyrocketed 445.23% in 2022.
  • Year by year, Other financing activities stood at $1.0 million in 2018, then tumbled by 54.34% to $469539.0 in 2019, then soared by 34.48% to $631453.0 in 2020, then surged by 59.63% to $1.0 million in 2021, then surged by 324.33% to $4.3 million in 2022.
  • Business Quant data shows Other financing activities for OPRX at $4.3 million in Q3 2022, $4.0 million in Q2 2022, and $3.2 million in Q1 2022.